 |
Opportunities for promoting an existing
neurological product as a neuroprotective agent for Parkinson's disease |
|
Opportunities and barriers associated
with promoting an anti-seizure product for behavioral/psychiatric therapy |
|
Opportunities and effective entry methods
associated with promoting an anti-spasticity product for migraine |
|
Effective approaches for simultaneously
entering the CHF and angina markets |
|
Methods of introducing a lower dose
anxiolytic as an allergy product |
